ArticleBMC cancer2008
Expression of estrogen receptor beta in the breast carcinoma of BRCA1 mutation carriers.
Article in BMC cancer, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- Characterization of the HER2 status in BRCA-mutated breast cancer: a single institutional series and systematic review with pooled analysis.ESMO open · 2022Pooled it
- Effects of Endocrine Interventions Targeting ERα or PR on Breast Cancer Risk in the General Population and Carriers ofInternational journal of molecular sciences · 2024Review
- Review
- Review
- Genomics and Functional Genomics of Malignant Pleural Mesothelioma.International journal of molecular sciences · 2020Review
- The role of estrogen receptor beta in breast cancer.Biomarker research · 2020Review
- Impact of Nuclear Oestrogen Receptor Beta Expression in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy.Geburtshilfe und Frauenheilkunde · 2019Article
- Clinical and pathologic characteristics of breast cancer patients carrying the c.3481_3491del11 mutation.Familial cancer · 2019Article
- Estrogen Signaling in ERα-Negative Breast Cancer: ERβ and GPER.Frontiers in endocrinology · 2018Review
- The biological effects and clinical implications of BRCA mutations: where do we go from here?European journal of human genetics : EJHG · 2016Review
- Biologic roles of estrogen receptor-β and insulin-like growth factor-2 in triple-negative breast cancer.BioMed research international · 2015Article
- DNA stabilization by the upregulation of estrogen signaling in BRCA gene mutation carriers.Drug design, development and therapy · 2015Article
- The pitfall of the transient, inconsistent anticancer capacity of antiestrogens and the mechanism of apparent antiestrogen resistance.Drug design, development and therapy · 2015Article
- ERβ1: characterization, prognosis, and evaluation of treatment strategies in ERα-positive and -negative breast cancer.BMC cancer · 2014Article
- Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2013Article
- Pathology of hereditary breast cancer.Cellular oncology (Dordrecht, Netherlands) · 2011Review
- Immunophenotypic predictive profiling of BRCA1-associated breast cancer.Virchows Archiv : an international journal of pathology · 2011Article
- ERalpha-negative and triple negative breast cancer: molecular features and potential therapeutic approaches.Biochimica et biophysica acta · 2009Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBreast cancers (BC) in women carrying mutations in BRCA1 gene are more frequently estrogen receptor negative than the nonhereditary BC. Nevertheless, tamoxifen has been found to have a protective effect in preventing contralateral tumors in BRCA1 mutation carriers. The identification of the second human estrogen receptor, ERbeta, raised a question of its role in hereditary breast cancer. The aim of this study was to assess the frequency of ERalpha, ERbeta, PgR (progesterone receptor) and HER-2 expression in breast cancer patients with mutated BRCA1 gene and in the control group.
methodsThe study group consisted of 48 women with BRCA1 gene mutations confirmed by multiplex PCR assay. The patients were tested for three most common mutations of BRCA1 affecting the Polish population (5382insC, C61G, 4153delA). Immunostaining for ERalpha, ERbeta and PgR (progesterone receptor) was performed using monoclonal antibodies against ERalpha, PgR (DakoCytomation), and polyclonal antibody against ERbeta (Chemicon). The EnVision detection system was applied. The study population comprised a control group of 120 BC operated successively during the years 1998-99.
resultsThe results of our investigation showed that BRCA1 mutation carriers were more likely to have ERalpha-negative breast cancer than those in the control group. Only 14.5% of BRCA1-related cancers were ERalpha-positive compared with 57.5% in the control group (P < 0.0001). On the contrary, the expression of ERbeta protein was observed in 42% of BRCA1-related tumors and in 55% of the control group. An interesting finding was that most hereditary cancers (75% of the whole group) were triple-negative: ERalpha(-)/PgR(-)/HER-2(-) but almost half of this group (44.4%) showed the expression of ERbeta.
conclusionIn the case of BRCA1-associated tumors the expression of ERbeta was significantly higher than the expression of ERalpha. This may explain the effectiveness of tamoxifen in preventing contralateral breast cancer development in BRCA1 mutation carriers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.